

Electronic Acknowledgement Receipt

EFS ID:	5096376
Application Number:	10612179
International Application Number:	
Confirmation Number:	5239
Title of Invention:	Method and medicament for inhibiting the expression of a given gene
First Named Inventor/Applicant Name:	Roland Kreutzer
Customer Number:	76634
Filer:	Allyson Russell Hatton
Filer Authorized By:	
Attorney Docket Number:	A2038-706120
Receipt Date:	03-APR-2009
Filing Date:	02-JUL-2003
Time Stamp:	18:58:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	4318
Deposit Account	502762
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part/.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	A2038_706120_IDS_ltr.pdf	22012 05176a2f1a425c03a7e77eebd3b0ff559b7 e615	no	1

Warnings:

Information:

2	NPL Documents	Burke_Appearance.pdf	558597 f11e2b55e4091b1cadf0c5d92d80a fe129	no	6
---	---------------	----------------------	--	----	---

Warnings:

Information:

3	NPL Documents	Barlow_Interferon.pdf	621344 e2e06fd23d11e3c21e95ae0f3713e5122 d65	no	7
---	---------------	-----------------------	--	----	---

Warnings:

Information:

4	NPL Documents	Decision_EP1144623_translation_032909.pdf	2370160 6e12775e2baed3b0d0d0f7841c26b9a b94df	no	50
---	---------------	---	---	----	----

Warnings:

Information:

5	NPL Documents	Decision_revoking_patent_and_grounds_033109.pdf	1293302 cf0310894ea02a5d900659e01026d550b cb85	no	33
---	---------------	---	--	----	----

Warnings:

Information:

6	NPL Documents	Harada_Absence.pdf	807102 c58965db80c4fc6e0fb0a7cb61b5fbef f66	no	10
---	---------------	--------------------	---	----	----

Warnings:

Information:

7	NPL Documents	Nakamura_RNase.pdf	1621543 9738d8bbc29e792d1d261a989a71bb 5bf	no	5
---	---------------	--------------------	--	----	---

Warnings:

Information:

8	NPL Documents	Not_Opp_Oppl_062008.pdf	806003 0250e177ebc135e1996bbd5eefabffde2 bfe6	no	24
---	---------------	-------------------------	---	----	----

Warnings:

Information:					
9	NPL Documents	Not_Opp_Pfizer_061908.pdf	573087 ddfd12900ff1ec0fb2601c3bd559f1700a27 4fe	no	15
Warnings:					
Information:					
10	NPL Documents	Not_Opp_Sanofi_061608.pdf	1102132 57618d0508cfca660a9a3007das8952b-H91 96ff	no	22
Warnings:					
Information:					
11	NPL Documents	Not_Opp_Silence_062008.pdf	780815 6ec5f34be66af39fcac0447cb3bb65cc92 875	no	19
Warnings:					
Information:					
12	NPL Documents	Not_Opp_Sirma_062008.pdf	1769300 23e928d0105e3d46e279a25d5953970414 28128	no	38
Warnings:					
Information:					
13	NPL Documents	Submission_Pfizer_DE10080167.pdf	183695 aae3ed21b05b5900d402fbae92019b702 4b7c	no	4
Warnings:					
Information:					
14	NPL Documents	Submission_Sirma_DE10080167_030409.pdf	1868728 cac6d70709ed7eda74e9997b3e79210e9c3 0f83d	no	35
Warnings:					
Information:					
15	NPL Documents	Submission_Oppl_DE10080167_030409.pdf	367768 975779530923437de51e0f5eb8371de7be 34b2b	no	7
Warnings:					
Information:					
16	NPL Documents	Patentees_Obser_DE10066235_Alnylam_020409.pdf	3097966 e0f2a1c77de4003ab9508c1159e6a768c 94589	no	58
Warnings:					
Information:					
17	NPL Documents	Patentees_observ_DE10080167_030409.pdf	367768 975779530923437de51e0f5eb8371de7be 34b2b	no	7
Warnings:					

Information:					
18	NPL Documents	Submission_Alnylam_trsl_DE1 0080167_030409.pdf	603222 ffd0f778b95407d8ff0a404eef703b0096d2 31dc3	no	21
Warnings:					
Information:					
19	Information Disclosure Statement (IDS) Filed (SB/08)	706121_sb08_040309.pdf	42167 bd1bbcb12ba870c70c54cb29fe0a56c1751c 280ec2	no	5
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
20	Fee Worksheet (PTO-06)	fee-info.pdf	29952 a1ff954e62930ac3bf69a425654f9c30d5ca de	no	2
Warnings:					
Information:					
Total Files Size (in bytes):				18886663	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					